← TrialMatch
HomeTrials

Transcranial Direct Current Stimulation for Treatment of Acute Ischemic Stroke

Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel t

Condition(s)Acute Ischemic Stroke
StatusRecruiting
PhasePhase 2
Study typeInterventional
SummaryMany patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the brain and rescue the brain tissue at risk of injury. The primary aim is to find an optimal dose of this therapy that is both adequately safe and effective on imaging markers of brain tissue rescue.
Who can participateInclusion Criteria: * New focal neurologic deficit consistent with AIS * National Institute of Health Stroke Scale (NIHSS) ≥4 or NIHSS\< 4 in the presence of disabling deficit (a deficit that, if unchanged, would prevent the * patient from performing basic activities of daily living such as bathing, ambulating, toileting, hygiene, and eating or returning to work) * Age\>18 * Presence of any cortical vessel occlusion, including Internal Carotid Artery, branches of Middle Cerebral Artery, Anterior Cerebral Artery, Posterior Cerebral Artery, Posterior-Inferior Cerebellar Artery * Presence of salvageable penumbra with perfusion lesion volume to ischemic core volume ratio of ≥ 1.2 on multimodal imaging * Patient ineligible for endovascular thrombectomy per American Heart/Stroke Associations Gui
Ages18 Years
SexAll
Lead sponsorUniversity of California, Los Angeles
LocationsLos Angeles, California, United States; Baltimore, Maryland, United States; Durham, North Carolina, United States
Start date2025-07-15
NCT IDNCT06440707
Official listinghttps://clinicaltrials.gov/study/NCT06440707

🔍 Search all trials →